Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 9/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 8/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.43 |
| ▸ | MBTD1 | Q05BQ5 | 2/20 | 0.41 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.41 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20744085 | 0.98 | L3MBTL3 (0.47) | L3MBTL3L3MBTL1CHRNA7CHRM1MBTD1 | |
| SCHEMBL20744086 | 0.98 | L3MBTL3 (0.47) | L3MBTL3L3MBTL1CHRNA7CHRM1MBTD1 | |
| SCHEMBL20744036 | 0.96 | CHRNA7 (0.50) | L3MBTL3L3MBTL1CHRNA7CHRM1HRH3 | |
| SCHEMBL28414360 | 0.96 | CHRNA7 (0.50) | L3MBTL3L3MBTL1CHRNA7CHRM1HRH3 | |
| SCHEMBL31664986 | 0.92 | CHRM1 (0.46) | L3MBTL3L3MBTL1CHRNA7CHRM1HRH3 | |
| SCHEMBL2908394 | 0.90 | CHRM1 (0.51) | L3MBTL3L3MBTL1CHRM1HRH3SIGMAR1 | |
| SCHEMBL3401436 | 0.90 | L3MBTL3 (0.57) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL29676554 | 0.90 | L3MBTL3 (0.57) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL3400330 | 0.90 | L3MBTL3 (0.57) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL18125956 | 0.89 | CHRM1 (0.50) | L3MBTL3L3MBTL1CHRM1HRH3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111278840-B | Pyrrolo [2,3-B ] pyridine compounds and their use for the treatment of cancer | 癌症研究科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| US-11447505-B1 | Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-09-20 | — | — | US | disclosed |
| EP-3668882-A1 | PYRROLO[2,3-B]PYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2020-06-24 | — | — | EP | disclosed |
| CN-111278840-A | Pyrrolo [2, 3-B ] pyridine compounds and their use for treating cancer | 癌症研究科技有限公司 | 2020-06-12 | — | — | CN | disclosed |
| WO-2019034890-A1 | PYRROLO[2,3-B]PYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11447505-B1 | Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer | PDXK, CCNK, CDC42BPB | L3MBTL3 4377/4885L3MBTL1 4747/4885CHRNA7 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.